Aptose announces FDA allowance of Investigational New Drug Application for CG-806
Aptose announced the FDA completed their review of the Company’s IND submission for CG-806. Aptose has been granted IND allowance to initiate its Phase 1 clinical trial amulticenter, open label, dose-escalation study with expansions to assess the safety, tolerability, PK, and efficacy of CG-806. March 25, 2019